The U.S. Food and Drug Administration (FDA) today granted 510(k) clearance for a global digital solution that supports the effective management of type 2 adult diabetes patients treated with basal insulin. The application will be marketed as Insulia® by the company Voluntis, which specializes in therapeutic companion software to help patients self-manage chronic diseases. Insulia® Diabetes Management Companion...
This issue highlights a special edition of ESAP, available for a limited time. Test your clinical knowledge with this free case to discover the rich intellectual legacy of endocrinology. Available on the online store. Clinical Vignette A 63-year-old man is referred for management of diabetes mellitus. His history is remarkable for adrenal insufficiency that occurred...
In hospitalized patients, hypoglycemia is associated with increased mortality risk, according to a study recently published in The Journal of Clinical Endocrinology & Metabolism. The paper comes as a coalition of diabetes stakeholders issues a strategic and actionable blueprint to address the deadly threat hypoglycemia poses to people with diabetes. (See the special section on...
As diabetes patients are living longer, endocrinologists are finding themselves faced with a unique set of treatment challenges not often found in younger patients. From cognitive function to cultural norms, treating older diabetes patients is much more complicated than ever before. During the Endocrine Society’s 97th annual meeting in San Diego, Pendar Farahani, MD, MSc,...
The U.S. Food and Drug Administration (FDA) last week granted 510(k) clearance for a new app-enabled blood glucose monitoring system. Ascensia Diabetes Care The device will be marketed as the CONTOUR® NEXT ONE Blood Glucose Monitoring System (BGMS) by Ascencia Diabetes Care. The CONTOUR NEXT ONE system features an blood glucose smart meter that links to...
Guidelines encourage comprehensive, personalized mental health assessment and treatment as part of routine diabetes care Living with diabetes can be challenging on many levels, and complex environmental, social, behavioral and emotional issues—known as psychosocial factors—influence the health of people living with the disease, as well as their ability to manage their diabetes. The American Diabetes...
Positive results were reported last week in a Phase 2b dose-ranging study, which met the primary endpoint of showing a statistically significant reduction in HbA1c at 16 weeks with delayed-release metformin compared with placebo in subjects with type 2 diabetes. Elcelyx Therapeutics is marketing this drug as Metformin DR, an investigational product designed to target metformin delivery to...
My friends and colleagues often remark that they hear so much about the epidemic of type 2 diabetes and the emphasis on weight loss, proper diet, and exercise to prevent it, they wonder what’s holding things up? Why can’t diabetes be prevented? What are the barriers? These are great and relevant questions. What is standing...